Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations

NCT04045613 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT04045613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04045613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 1/2
Overall status
Completed
Start date
August 2, 2019
Completion date
October 4, 2022
Enrollment
95 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma